118 related articles for article (PubMed ID: 8616908)
1. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.
Teicher BA; Holden SA; Ara G; Korbut T; Menon K
Cancer Chemother Pharmacol; 1996; 38(2):169-77. PubMed ID: 8616908
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
Kakeji Y; Teicher BA
Invest New Drugs; 1997; 15(1):39-48. PubMed ID: 9195288
[TBL] [Abstract][Full Text] [Related]
3. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
Teicher BA; Dupuis NP; Robinson MF; Emi Y; Goff DA
Oncol Res; 1995; 7(5):237-43. PubMed ID: 8534929
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
Herbst RS; Takeuchi H; Teicher BA
Cancer Chemother Pharmacol; 1998; 41(6):497-504. PubMed ID: 9554595
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Teicher BA; Sotomayor EA; Huang ZD
Cancer Res; 1992 Dec; 52(23):6702-4. PubMed ID: 1384969
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Teicher BA; Holden SA; Dupuis NP; Kakeji Y; Ikebe M; Emi Y; Goff D
Breast Cancer Res Treat; 1995; 36(2):227-36. PubMed ID: 8534870
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
Teicher BA; Korbut TT; Menon K; Holden SA; Ara G
Cancer Chemother Pharmacol; 1994; 33(6):515-22. PubMed ID: 8137463
[TBL] [Abstract][Full Text] [Related]
9. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D
Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911
[TBL] [Abstract][Full Text] [Related]
10. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
[TBL] [Abstract][Full Text] [Related]
11. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
Teicher BA; Holden SA; Ara G; Northey D
Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
[TBL] [Abstract][Full Text] [Related]
12. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Kato T; Sato K; Kakinuma H; Matsuda Y
Cancer Res; 1994 Oct; 54(19):5143-7. PubMed ID: 7522956
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.
Teicher BA; Holden SA; Ara G; Sotomayor EA; Huang ZD; Chen YN; Brem H
Int J Cancer; 1994 Jun; 57(6):920-5. PubMed ID: 7515861
[TBL] [Abstract][Full Text] [Related]
14. Increased efficacy of chemo- and radio-therapy by a hemoglobin solution in the 9L gliosarcoma.
Teicher BA; Dupuis NP; Emi Y; Ikebe M; Kakeji Y; Menon K
In Vivo; 1995; 9(1):11-8. PubMed ID: 7669943
[TBL] [Abstract][Full Text] [Related]
15. In vivo modulation of several anticancer agents by beta-carotene.
Teicher BA; Schwartz JL; Holden SA; Ara G; Northey D
Cancer Chemother Pharmacol; 1994; 34(3):235-41. PubMed ID: 8004757
[TBL] [Abstract][Full Text] [Related]
16. 2-Deoxy-D-glucose enhances dichloroacetate antitumor action against Lewis lung carcinoma.
Pyaskovskaya ON; Kolesnik DL; Fedorchuk AG; Prokhorova IV; Solyanik GI
Exp Oncol; 2016 Sep; 38(3):176-80. PubMed ID: 27685525
[TBL] [Abstract][Full Text] [Related]
17. Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model.
McDonnell CO; Holden G; Sheridan ME; Foley D; Moriarty M; Walsh TN; Bouchier-Hayes DJ
J Surg Res; 2004 Jan; 116(1):19-23. PubMed ID: 14732345
[TBL] [Abstract][Full Text] [Related]
18. The antitumor effect of postoperative treatment with genistein alone or combined with cyclophosphamide in mice bearing transplantable tumors.
Wietrzyk J; Opolski A; Madej J; Radzikowski C
Acta Pol Pharm; 2000 Nov; 57 Suppl():5-8. PubMed ID: 11293263
[TBL] [Abstract][Full Text] [Related]
19. CAI: effects on cytotoxic therapies in vitro and in vivo.
Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
[TBL] [Abstract][Full Text] [Related]
20. Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling.
Cline EI; Bicciato S; DiBello C; Lingen MW
Cancer Res; 2002 Dec; 62(24):7143-8. PubMed ID: 12499246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]